Comparison of the protective efficacy of Aujeszky's disease (pseudorabies) virus glycoproteins obtained from different sources

Puentes, Eugenia; Eiras, A.; Cancio, Esperanza; Nores, M. V.; Aguilera, Antonio; Prado, Rafael Seoane; Regueiro, Benito J.

doi:10.1016/0378-1135(93)90115-n

Cited by 5 publications

(6 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although vaccination confers protection against disease, it does not prevent infection from a wild-type strain. Thus, both the virus in the vaccine and the super-virulent wild-type strain can establish latency within the same animal ( 13 – 15 ). …”

mentioning

confidence: 99%

Pathogenic Pseudorabies Virus, China, 2012

Yu¹,

Zhou²,

Hu³

et al. 2014

Emerg. Infect. Dis.

186

128

View full text Add to dashboard Cite

show abstract

mentioning

confidence: 99%

Pathogenic Pseudorabies Virus, China, 2012

Yu¹,

Zhou²,

Hu³

et al. 2014

Emerg. Infect. Dis.

186

128

View full text Add to dashboard Cite

show abstract

“…In the present work such an ISCOM was compared, both in mice and pigs, with the traditional oily adjuvant. Since ISCOMs can only be formed using solubilized proteins and not from viral particles, they were prepared from a SHV-1 glycoprotein preparation, previously reported as protective when adjuvated with oil (PUENTES et al, 1993). In order to immunomodulate the cellular response, ISCOMs were also obtained from a mixture of viral glycoproteins and Mab anti-CD3.…”

Section: Discussionmentioning

confidence: 99%

“…SHV-1 encodes at least six glycoproteins designated gI, gII, gIII, gp50, gp63 and gX that, with the exception of gX, are located in the virus envelope as well as the plasma membrane of infected cells (HAMPL et al, 1984;LUKACS et al, 1985;BEN-PORAT et al, 1986). The protective efficacy of SHV-1 glycoprotein preparations seems to be greater, both in mice and pigs, when glycoproteins are purified from infected cell membranes than from mature virions (PUENTES et al, 1993). These glycoproteins might Apparent molecular weight in kDa are indicated act as antigens for new vaccines, but they tend to be poorly immugenic and to require adjuvants (ALLISON and GREGORIADIS, 1990;EIRAS et al, 1992;PUENTES et al, 1993).…”

Section: Introductionmentioning

confidence: 99%

“…The protective efficacy of SHV-1 glycoprotein preparations seems to be greater, both in mice and pigs, when glycoproteins are purified from infected cell membranes than from mature virions (PUENTES et al, 1993). These glycoproteins might Apparent molecular weight in kDa are indicated act as antigens for new vaccines, but they tend to be poorly immugenic and to require adjuvants (ALLISON and GREGORIADIS, 1990;EIRAS et al, 1992;PUENTES et al, 1993).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Efficacy of Various Non‐Oily Adjuvants in Immunization Against the Aujeszky's Disease (Pseudorabies) Virus

Puentes

Cancio

Eiras

et al. 1993

Journal of Veterinary Medicine, Series B

Self Cite

View full text Add to dashboard Cite

Summary Standard oil and various non‐oily adjuvants were compared for use in immunization against the Aujeszky's disease (pseudorabies) virus, both in mice and swine, and using either inactivated virions or purified glycoproteins as antigen. Mineral oil, sodium alginate, aluminium hydroxide, and saponin were assayed in mice as adjuvants for inactivated virions, saponin being the most efficient. The addition of Mab anti‐CD3 did not improve either immune response or protection achieved in mice using viral particles with oil or sodium alginate. When purified glycoproteins were used as antigens, the use of ISCOM greatly enhanced specific T‐cell responses and protection of mice. The incorporation of Mab anti‐CD3 into ISCOM conferred 100 % protection of mice. Surprisingly, when an ISCOM containing glycoproteins was assayed in swine in a single‐dose trial, no improvement on the protection conferred by the oily adjuvant was observed.

show abstract

“…Laboratory attenuated ADV replicate well in many types of cells e.g., BHK 21 cells (Puentes et al 1993) or PK-15 cells (Afshar and Dulac 1986;Markusˇ-Cizelj et al 1991) which can be used to produce a vaccine against AD. This vaccine can be produced either by traditional cell culture systems, such as roller bottles, spinner flasks or bioreactors.…”

Section: Introductionmentioning

confidence: 99%

BHK 21 C13 cells for Aujeszky’s disease virus production using the multiple harvest process

et al. 2004

View full text Add to dashboard Cite

Production of Aujeszky's disease virus (ADV) from BHK 21 C13 suspension cells using a simple harvest and multiple harvest process mode was examined. We studied growth kinetics of BHK 21 C31 cells in 750 ml spinner flask containing 500 ml of culture medium. In the simple harvest process of ADV production, 425 ml of virus harvest was obtained with a virus titer of 10 6.4 TCID 50 ml À1 which corresponds to 10,676 doses of vaccine. The multiple harvest process resulted in 850 ml of virus harvest with a virus titer of 10 6.5 TCID 50 ml À1 corresponding to 26,877 AD vaccine doses. In conclusion, the multiple harvest process mode using BHK 21 C13 can be considered as a favorable process to produce ADV.

show abstract

Comparison of the protective efficacy of Aujeszky's disease (pseudorabies) virus glycoproteins obtained from different sources

Cited by 5 publications

References 22 publications

Pathogenic Pseudorabies Virus, China, 2012

Pathogenic Pseudorabies Virus, China, 2012

Efficacy of Various Non‐Oily Adjuvants in Immunization Against the Aujeszky's Disease (Pseudorabies) Virus

BHK 21 C13 cells for Aujeszky’s disease virus production using the multiple harvest process

Contact Info

Product

Resources

About